Thigpen 1989.

Methods	Randomised Phase II trial April 1982 to July 1985
Participants	331 women with advanced or recurrent squamous cell cervical cancer no longer amenable to control by surgery or radiotherapy
Interventions	Arm 1: cisplatin 50 mg/m2 iv rate 1 mg/minute q21 days Arm 2: cisplatin 50 mg/m2 iv rate over 24 h q21 days
Outcomes	Response rates OS PFS Toxicity
Notes	63 patients deemed ineligible (7 other primary site, 4 second primary, 26 wrong histological subtype, 26 no documentation of cervical primary, 1 elevated blood nitrogen urea at entry, 1 GOG performance status 4 at entry). 6 further patients with unevaluable (1 clerical error at entry, 1 never treated, 1 inadequate pathology, 2 inadequate data submitted, 1 not documented reason for unevaluability)
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Latin square arrangement balancing the sequence of assigned regimens within and across institutions
Allocation concealment (selection bias)	Unclear risk	Not documented
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Not documented but OS unlikely to be affected by blinding
Incomplete outcome data (attrition bias) All outcomes	High risk	63 patients excluded as ineligible and further 6 patients were unevaluable balanced across groups
Selective reporting (reporting bias)	Low risk	Published report included all pre‐specified outcomes
Other bias	Low risk	No hint at any other possible biases